多西他赛联合奥沙利铂治疗晚期非小细胞肺癌34例临床观察

Treatment of advanced non-small cell lung cancer with combination therapy of docetaxel and oxaliplatin:A report of 34 cases

目的:观察多西他赛联合奥沙利铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应。方法:选择Ⅲb期、Ⅳ期NSCLC癌患者34例(Karnofsky评分≥60分,预计生存期≥3个月),多西他赛75 mg/m2,静脉滴注,第1天;奥沙利铂130 mg/m2,静脉滴注,第2天。21天为1周期,连用2周期后评定疗效。结果:34例均可评价疗效,部分缓解(PR)8例,稳定(SD)19例,进展(PD)7例,总有效率(CR+PR)为23.5%。主要毒副反应为外周神经炎和骨髓抑制。结论:多西他赛联合奥沙利铂治疗晚期NSCLC癌有效,毒副反应可耐受,尤适于老年耐药患者。

Objective：To observe the effect and side effect of docetaxel combined with oxaliplatin in the treatment of non-small cell lung cancer（NSCLC）. Methods ：Thirty-four patients with advanced NSCLC （Karnofsky score ≥60, expectancy life span ≥3 months） were included in the sstudy. Docetaxel 75 mg/m2 was administrated in intravenous infusion at day 1 and oxaliplatin 130 mg/m2 was administrated at day 2. One cycle consisted of 21 days and the clinical response was assessed after two cycles. Results： Of the 34 patients,CR was achieved in 0,PR in 8 ,SD in 19 and PD in 7. The response rate was 23.5%. The main side effects were peripheral neuritis and inhibition of bone marrow. Conclusions：Combination therapy of docetaxel and oxaliplatin is effective on advanced NSCLC with acceptable toxicity and especially suitable for elderly and drug resistant patients.